Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06774079 · ClinicalTrials.gov registry record · Phase 4
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
A Phase 4 study of Crohn Disease, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06774079 is a Phase 4 study of Crohn Disease that is actively recruiting participants, run by University of Miami. The registered enrollment target is 24 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06774079, a Phase 4 study of Crohn Disease, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) for Crohn's disease patients with mild disease who are on stable doses of biologic medication (infliximab or adalimumab) and who have a body mass index (BMI) of at least 27.
Conditions Studied
Interventions
- DRUG Tirzepatide
- BEHAVIORAL Mediterranean diet
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2026-03-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06774079
The ClinicalTrials.gov registry entry for NCT06774079 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (88% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06774079 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06774079 about?
NCT06774079 is a clinical study titled "Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients". The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) f...
What is the current status of trial NCT06774079?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2025-03-05. Estimated completion is 2026-03-05.
What conditions does trial NCT06774079 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT06774079?
The interventions under investigation include: Tirzepatide (DRUG), Mediterranean diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT06774079?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06774079 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
-
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RECRUITING · Phase 4
-
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
ACTIVE NOT RECRUITING · Phase 4
-
Triple Combination Therapy in High Risk Crohn's Disease (CD)
COMPLETED · Phase 4
-
Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
COMPLETED · Phase 4
-
Flagyl Microbiome in Crohn's Disease
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.